Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2013, Article ID 891391, 9 pages
http://dx.doi.org/10.1155/2013/891391
Research Article

Practical Guidance for Implementing Predictive Biomarkers into Early Phase Clinical Studies

Merck Research Laboratories, Clinical Biomarkers and Diagnostics Laboratory, 126 E. Lincoln Avenue, Rahway, NJ 07065, USA

Received 28 June 2013; Accepted 11 September 2013

Academic Editor: Sudhish Mishra

Copyright © 2013 Matthew J. Marton and Russell Weiner. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. Nohaile, “The biomarker is not the end,” Drug Discovery Today, vol. 16, no. 19-20, pp. 878–883, 2011. View at Publisher · View at Google Scholar · View at Scopus
  2. R. Xie, J.-Y. Chung, K. Ylaya et al., “Factors influencing the degradation of archival formalin-fixed paraffin-embedded tissue sections,” Journal of Histochemistry and Cytochemistry, vol. 59, no. 4, pp. 356–365, 2011. View at Publisher · View at Google Scholar · View at Scopus
  3. The cobas 4800 BRAF V600 Mutation Test Product Insert, 2012, http://www.accessdata.fda.gov/cdrh_docs/pdf11/P110020c.pdf.
  4. M. Maak, I. Simon, U. Nitsche et al., “Independent validation of a prognostic genomic signature (ColoPrint) for patients with stage II colon cancer,” Annals of Surgery, vol. 257, no. 6, pp. 1053–1058, 2013. View at Publisher · View at Google Scholar
  5. D. A. Eberhard, G. Giaccone, and B. E. Johnson, “Biomarkers of response to epidermal growth factor receptor inhibitors in non-small-cell lung cancer working group: standardization for use in the clinical trial setting,” Journal of Clinical Oncology, vol. 26, no. 6, pp. 983–994, 2008. View at Publisher · View at Google Scholar · View at Scopus
  6. W. C. Olson, M. E. Smolkin, E. M. Farris et al., “Shipping blood to a central laboratory in multicenter clinical trials: effect of ambient temperature on specimen temperature, and effects of temperature on mononuclear cell yield, viability and immunologic function,” Journal of Translational Medicine, vol. 9, article 26, 2011. View at Publisher · View at Google Scholar · View at Scopus
  7. S. Duenwald, M. Zhou, Y. Wang et al., “Development of a microarray platform for FFPET profiling: application to the classification of human tumors,” Journal of Translational Medicine, vol. 7, article 65, 2009. View at Publisher · View at Google Scholar · View at Scopus
  8. FDA News Release P07-13, “FDA clears breast cancer specific molecular prognostic test,” News & Events, February 2007, http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2007/ucm108836.htm.
  9. FDA News Release, “FDA clears test that helps identify type of cancer in tumor sample,” News & Events, February 2007, http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2008/ucm116931.htm.
  10. FDA News Release Approval of Kras test, “FDA approves genetic test to help some colon cancer patients, physicians considering Erbitux therapy,” News & Events, July 2012, http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm310899.htm.
  11. A. S. Gargis, L. Kalman, M. W. Berry et al., “Assuring the quality of next-generation sequencing in clinical laboratory practice,” Nature Biotechnology, vol. 30, no. 11, pp. 1033–1036, 2012. View at Publisher · View at Google Scholar
  12. E. A. Perez, V. J. Suman, N. E. Davidson et al., “HER2 testing by local, central, and reference laboratories in specimens from the north central cancer treatment group N9831 intergroup adjuvant trial,” Journal of Clinical Oncology, vol. 24, no. 19, pp. 3032–3038, 2006. View at Publisher · View at Google Scholar · View at Scopus
  13. T. André, H. Blons, M. Mabro et al., “Panitumumab combined with irinotecan for patients with KRAS wild-type metastatic colorectal cancer refractory to standard chemotherapy: a GERCOR efficacy, tolerance, and translational molecular study,” Annals of Oncology, vol. 24, no. 2, pp. 412–419, 2013. View at Publisher · View at Google Scholar
  14. E. Bellon, M. J. L. Ligtenberg, S. Tejpar et al., “External quality assessment for KRAS testing is needed: setup of a European program and report of the first joined regional quality assessment rounds,” Oncologist, vol. 16, no. 4, pp. 467–478, 2011. View at Publisher · View at Google Scholar · View at Scopus
  15. FDA Draft Guidance for Industry and FDA Staff, “Commercially Distributed in Vitro Diagnostic Products Labeled for Research Use Only or Investigational Use Only: Frequently Asked Questions,” June 2011.
  16. FDA Draft Guidance for Industry, Clinical Laboratories, and FDA Staff. In Vitro Diagnostic Multivariate Index Assays, July 2007.
  17. FDA Draft Guidance for Industry and FDA Staff. In Vitro Companion Diagnostic Devices, July 2011.